Lantheus Holdings, Inc. (NASDAQ:LNTH) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have received an average rating of “Moderate Buy” from the seven brokerages that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $99.17.

A number of analysts have recently issued reports on LNTH shares. B. Riley raised their price target on shares of Lantheus from $95.00 to $99.00 and gave the company a “buy” rating in a report on Thursday, April 18th. Mizuho raised their price objective on shares of Lantheus from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, May 3rd. Truist Financial raised their price objective on shares of Lantheus from $82.00 to $96.00 and gave the stock a “buy” rating in a report on Friday, May 3rd. Finally, StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a report on Friday, May 3rd.

Lantheus Stock Performance

Shares of NASDAQ LNTH opened at $81.31 on Friday. The firm’s 50-day moving average price is $77.08 and its 200-day moving average price is $66.01. The company has a quick ratio of 4.55, a current ratio of 4.84 and a debt-to-equity ratio of 0.59. The company has a market cap of $5.64 billion, a PE ratio of 12.41 and a beta of 0.56. Lantheus has a 52-week low of $50.20 and a 52-week high of $91.81.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.51 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.11. The firm had revenue of $369.98 million for the quarter, compared to the consensus estimate of $349.46 million. Lantheus had a net margin of 33.72% and a return on equity of 54.10%. As a group, analysts anticipate that Lantheus will post 6.51 EPS for the current year.

Insider Activity

In other news, Director Heinz Christoph Maeusli sold 18,373 shares of Lantheus stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $79.19, for a total transaction of $1,454,957.87. Following the sale, the director now owns 23,340 shares in the company, valued at $1,848,294.60. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, CAO Andrea Sabens sold 341 shares of the firm’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $76.89, for a total value of $26,219.49. Following the completion of the transaction, the chief accounting officer now directly owns 62,898 shares of the company’s stock, valued at $4,836,227.22. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Heinz Christoph Maeusli sold 18,373 shares of the firm’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $79.19, for a total transaction of $1,454,957.87. Following the completion of the transaction, the director now directly owns 23,340 shares of the company’s stock, valued at $1,848,294.60. The disclosure for this sale can be found here. Insiders have sold a total of 32,269 shares of company stock worth $2,557,300 over the last quarter. Insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. grew its holdings in shares of Lantheus by 5.6% in the first quarter. Vanguard Group Inc. now owns 7,362,969 shares of the medical equipment provider’s stock valued at $458,271,000 after purchasing an additional 389,828 shares in the last quarter. Westfield Capital Management Co. LP boosted its stake in Lantheus by 25.3% during the first quarter. Westfield Capital Management Co. LP now owns 1,958,018 shares of the medical equipment provider’s stock worth $121,867,000 after buying an additional 394,837 shares during the period. Farallon Capital Management LLC boosted its stake in Lantheus by 595.3% during the first quarter. Farallon Capital Management LLC now owns 1,483,227 shares of the medical equipment provider’s stock worth $92,316,000 after buying an additional 1,269,900 shares during the period. Reinhart Partners LLC. boosted its stake in Lantheus by 8.4% during the first quarter. Reinhart Partners LLC. now owns 1,470,383 shares of the medical equipment provider’s stock worth $91,517,000 after buying an additional 114,110 shares during the period. Finally, American Century Companies Inc. boosted its stake in Lantheus by 41.9% during the third quarter. American Century Companies Inc. now owns 1,300,904 shares of the medical equipment provider’s stock worth $90,387,000 after buying an additional 384,093 shares during the period. 99.06% of the stock is owned by hedge funds and other institutional investors.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.